ClinicalTrials.gg
CompletedNCT00321412Updated May 30, 2014

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

A Phase 3 interventional study of AST-120 in Inflammatory Bowel Disease and Intestinal Fistula, sponsored by Ocera Therapeutics. Completed at 88 sites in 12 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-05-30.

Sponsored by Ocera Therapeutics (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 463 studies in Inflammatory Bowel Diseases with a site in United States — 103 open to participants now, 124 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United States.

Enrollment
55th of 327
191 · median 50
Started
2006
with 14 others
Phase 3
41 of 463
4 open now
Registered
19th of 463
by date

Among the 463 studies in Inflammatory Bowel Diseases with a site in United States, this one is the 55th largest by enrollment of the 327 interventional ones that give a count, is one of 15 that started in 2006, is one of 41 in phase 3, and was the 19th registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

103 of the 463 studies in Inflammatory Bowel Diseases with a site in United States are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Inflammatory Bowel Diseases with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with mild to moderately severe Crohn's disease who have fistulas. The study will test whether or not patients receiving AST-120 experience a greater reduction in number of draining fistulas and improvement of their other Crohn's disease symptoms versus patients who receive placebo (material that does not contain any active medication).

Read the detailed description

The experimental drug AST-120 is composed of black, odorless spherical carbon particles in 2g sachets (aluminum foil pouches). The placebo consists of microcrystalline cellulose spheres, Celphere CP-305, stained to match the appearance of AST-120, in 2g sachets (aluminum foil pouches). Both AST-120 and placebo are oral (taken by mouth)preparations. Both are tasteless. To take the product, patients will tear open the sachets, drop the contents directly on their tongue and wash it down with 8 ounces of water.

Patients will be randomly assigned (like the toss of a coin), to receive either AST-120 or placebo. Patients will have a 50/50 chance of receiving placebo. Patients who participate in this study will be required to take a single dose of study drug (AST-120 or placebo) 3 times a day, 30 minutes after a meal, for 8 weeks, and be evaluated at Week 4 and Week 8. This is a 'blinded' treatment, which means that neither the patient nor the study doctor will know if the patient has received study drug or placebo.

If, at the end of the first full course of randomized treatment, (8 weeks), patients are not showing an improvement in their condition, they may have the option to receive the alternate blinded treatment for one treatment course (8 weeks). The study doctor will discuss this option with each patient individually. During this second course of treatment, patients will be evaluated at Week 12 and Week 16. If the patient does not respond to the alternate blinded treatment, or their condition worsens after 4 weeks (assessed at Week 12), they may be removed from the study at the discretion of the investigator.

If patients respond to either the initial treatment or the alternate blinded treatment, they will have monthly doctor/clinic visits for up to 6 months (Week 24), or until their condition worsens or they relapse. Patients will not receive any study drug during this follow-up period.

Relapse is defined for this study as:

  • an increase by 1 or more in the number of draining fistulas for 2 sequential visits versus the number present at the time of response (response is defined as at least a 50% reduction in the number of draining fistulas at either Week 8, or for those patients receiving alternate blinded treatment, Week 16).

There are a maximum of 8 patient evaluation visits in this study (Screen, Baseline, Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24). Evaluations at most of these visits include a review of concomitant medications, medical history/adverse events, physical exam, fistula exam, blood draws for safety labs, urine pregnancy tests for females, and measurement of body weight. Patients will also be asked to keep a daily diary to record frequency of bowel movements, general well-being, and use of antidiarrheal medication.

Treatment failure in this study is defined by one or more of the following occurring prior to Week 8:

  • The need for additional therapies or dose increase for treatment of Crohn's disease, including an increase of corticosteroid dose to higher than baseline
  • Clinical/symptomatic development of an abscess
  • Clinical/symptomatic evidence of stricture
  • The need for surgical intervention for Crohn's disease
  • The patient withdraws from the study

Patients will be discontinued from the study at any time if one or more of the following complications occur:

  • Development of an abscess or symptomatic stricture
  • The need for surgical intervention for Crohn's disease
  • Occurrence of any other event that in the opinion of the investigator warrants discontinuation of the patient from the study

In addition, patients whose CDAI score has risen by > or = 70 points above baseline or risen above 400 will be discontinued from the study.

Administration of any additional therapies or dose increases of concomitant medications (including corticosteroids) to control Crohn's disease to higher than baseline while receiving study drug (initial randomized treatment or alternate blinded treatment) will require discontinuation of the patient from the study.

Discontinued patients will be evaluated in a termination visit to document the lack of treatment efficacy and no further study treatment will be given.

03

Conditions studied

  • Inflammatory Bowel Disease
  • Intestinal Fistula

Keywords

  • Crohn's disease
  • IBD
  • Inflammatory Bowel Disease
  • Fistula
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body Weight > or = 40kg
  • Documented diagnosis of Crohn's disease, including patients with documented diagnosis of ileitis, colitis, or ileocolitis
  • Presence of at least one draining fistula. Patients with enterocutaneous fistulas can be included if they have > or = 1 draining perianal fistula. Women with rectovaginal fistulas can be included if they have > or = 1 draining perianal fistula.
  • Crohn's Disease Activity Index (CDAI) score \< 400
  • count (thrombocytes) > or = 100,000/uL
  • Able and willing to comply with all protocol procedures for the duration of the study
  • Able and willing to understand, sign and date an document, and authorize access to protected health information
  • Females must be , surgically incapable of bearing children, or practicing a reliable method of (hormonal contraceptives, intrauterine devices, spermicide and barrier). Partner/spouse sterility may also qualify at the Investigator's discretion. Females of must have a negative urine pregnancy test at baseline.

Exclusion criteria

Exclusion Criteria:

  • Non-response to infliximab or other biological / immunomodulators for fistulas associated with Crohn's disease (response is defined as a > or = 50% reduction from baseline in the number of fistulas over at least four weeks); patients who respond once to infliximab and eventually fail can be included
  • Infliximab (and/or other biological immunosuppressant/immunomodulatory) therapy within 3 months prior to enrollment in the study
  • Presence of symptomatic strictures or suggestion of significant clinical obstruction
  • Patients with setons are excluded, unless the setons are removed within 48 hours prior to study entry
  • Presence of entero-entero, recto-vesicular, entero-vesicular fistulas
  • count (thrombocytes) \< 100,000/uL
  • CDAI score of > or = 400
  • Patient is unable to stay on a stable dose of concomitant Crohn's disease medication(s) for at least 10 weeks in the opinion of the investigator
  • Currently symptomatic untreated diarrhea due to conditions other than mild to moderately active Crohn's disease (e.g., bacterial or parasitic gastroenteritis, bile salt diarrhea, etc.)
  • Severe diarrhea defined by > 10 liquid bowel movements per day
  • Other local manifestations of mild to moderately active Crohn's disease such as abscesses, or other disease manifestations for which surgery might be indicated or which might preclude utilization of a CDAI to assess response to therapy (e.g., short bowel syndrome)
  • Presence of an ileostomy
  • Receiving Total Parenteral Nutrition (TPN) as the sole source of nutrition within 3 weeks of Screen
  • Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling.
  • \< 8.5 g/dL (females) or hemoglobin \< 10 g/dL (males) at Screen
  • Women who are pregnant, breast feeding, or planning to become pregnant during the study
  • Other major physical or major psychiatric illness within the last 6 months that in the opinion of the investigator would affect the patient's ability to complete the trial
  • Uncontrolled systemic disease
  • Patients undergoing chemotherapy for the treatment of cancer
  • Known or to any component of the test product (study drugs) or diagnostics used
  • Participation in another study within eight (8) weeks prior to the study
  • Unable to attend all visits required by the protocol
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
191 participants (actual)

Study arms

  • Placebo comparator
    2

    Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets

    Drug: AST-120

  • Experimental
    1

    AST-120, 2 gram sachets

    Drug: AST-120

Interventions

  • DrugAST-120

    Drug pages: AST 120 · Charcoal

    oral, sachet, 2 grams three times daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Efficacy: The proportion of patients considered to be "treatment successes" defined by a reduction of at least 50% in the number of draining fistulas at both week 4 and week 8 of an 8 week treatment period

    Time frame: 8 weeks

  2. Safety: Adverse events deemed possibly, probably or definitely related to study drug during 8 weeks of treatment

    Time frame: 8 weeks

Secondary outcomes

  1. Efficacy: 100% non-draining fistulas at both week 4 and week 8

    Time frame: 8 weeks

  2. Efficacy: Fistula response at Week 8

    Time frame: 8 weeks

  3. Efficacy: Change in CDAI scores from baseline over 8 weeks of treatment

    Time frame: 8 weeks

  4. Safety: Clinical laboratory tests (electrolytes)

    Time frame: 8 weeks

  5. Safety: Development of abscesses

    Time frame: 8 weeks

  6. Safety: Physical examination, vital signs (blood pressure, heart rate, respiration rate and temperature)

    Time frame: 8 weeks

07

Study locations

88 sites
  • Advanced Clinical Research Institute
    Anaheim, California 92801, United States
  • Digestive Care Medical Center
    San Carlos, California 94070, United States
  • Shafran Gasteroenterology Center
    Winter Park, Florida 32789, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637-1426, United States
  • Indiana University, Outpatient Clinical Research Facility
    Indianapolis, Indiana 46202, United States
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
  • University of Louisville, Department of Surgery
    Louisville, Kentucky 40202, United States
  • Metropolitan Gastroenterology Group/Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Drs. Scherf, Chessler, Zingler & Spinnell, MD, PA
    Fort Lee, New Jersey 07024, United States
  • Long Island Clinical Research Associates, LLP
    Great Neck, New York 11021, United States
  • Mount Sinai School of Medicine, IBD Research Center
    New York, New York 10028, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
  • Carolina Digestive Health Associates
    Charlotte, North Carolina 28211, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic - Department of Gastroenterology
    Cleveland, Ohio 44195, United States
  • The Penn State University, Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Digestive Disease Center/MUSC
    Charleston, South Carolina 29425, United States
  • Memphis Gastroenterology Group, PC
    Germantown, Tennessee 38138, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • Dean Foundation Research Center
    Madison, Wisconsin 53715, United States
  • Univ Klinik fur Innere Medizin Innsbruck
    Innsbruck, 6020, Austria
  • Universitatsklinik fur Innere Medizin I der PMU
    Salzburg, 5020, Austria
  • AKH Wien - Univ Klinik Innere Med IV
    Wien, 1090, Austria
  • Imelda General Hospital
    Bonheiden, B-2820, Belgium
  • St. Jansziekenhuis/Ziekenhuis Oost-Limburg
    Genk, 3600, Belgium
  • University Hospital Gasthuisberg, University of Leuven
    Leuven, 3000, Belgium
  • H.-Hartziekenhuis Roeselare-Menen vzw
    Roeselare, 8800, Belgium
  • GILDR Group, University of Edmonton
    Edmonton, Alberta T6G 2X8, Canada
  • Liver & Intestinal Research Centre
    Vancouver, British Columbia V5Z 1H2, Canada
  • McMaster University Medical Centre
    Hamilton, Ontario L8N 3Z5, Canada
  • London Health Sciences Center
    London, Ontario N6A 4G5, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T 1E2, Canada
  • University Hospital Brno, Internal and Gastroenterology Department
    Brno, 625 00, Czech Republic
  • Regional Hospital Liberec, Department of Gastroenterology
    Liberec, 460 63, Czech Republic
  • University Hospital Prague 2, 4th Department of Internal Medicine
    Prague 2, 120 00, Czech Republic
  • Thomayer's University Hospital Prague, 2nd Internal Department
    Prague 4, 140 00, Czech Republic
  • Institute for Clinical and Experimental Medicine
    Prague 4, 140 21, Czech Republic
  • CHU Hopital Nord, Service de Gastro-enterologie et nutrition
    Amiens, 80054, France
  • Hopital de la Cote de Nacre - CHU
    Caen, 14033, France
  • CHU de Grenoble - Hopital Nord
    Grenoble, 38043, France
  • Hopital Claude Huriez, Service des maladies de l'appareil disgestif
    Lille, 59037, France
  • Hopital Nord, Service de Gastro-Enterologie
    Marseille, 13915, France
  • Hopital Saint-Eloi, Service de Gastro-enterologie et transplantation
    Montpelier, 34295, France
  • CHU Hotel Dieu, Institut des Maladies de l'Appareil Digestif
    Nantes, 44093, France
  • CHU de Nice - Hopital de l'Archet 2
    Nice, 06202, France
  • Hopital Leopold Bellan
    Paris, 75674, France
  • Universitatsklinikum Aachen
    Aachen, 52074, Germany
  • Charite-Campus Virchow-Klinikum
    Berlin, D-13353, Germany
  • Klinikum der Johann-Wolfgang-Goethe Universitat Frankfurt am Main
    Frankfurt, 60590, Germany
  • Medizinische Hochschule Hannover
    Hannover, D-30623, Germany
  • Universitatsklinik Heidelberg Abteilung Gastroenterologie und Hepatologie
    Heidelberg, D-69120, Germany
  • Universitatsklinikum Schleswig-Holstein
    Kiel, D-24105, Germany
  • Klinikum rechts der Isar der TUM II
    Munchen, 81675, Germany
  • Universitatsklinikum Regensburg
    Regensburg, 93047, Germany
  • Universitat Rostock - Midizinische Fakultat
    Rostock, D-18057, Germany
  • Medizinische Universitatsklinik Tubingen
    Tubingen, D-72026, Germany
  • Universitatsklinikum Ulm
    Ulm, D-89081, Germany
  • Peterfy Sandor utcai Korhaz-Rendelointezet
    Budapest, H-1076, Hungary
  • Semmelweis Egyetem
    Budapest, H-1083, Hungary
  • Semmelweis Egyetem
    Budapest, H-1088, Hungary
  • Miskolc Megyei Jogu Onkormanyzat Semmelweis Oktato Korhaz-Rendelointezet
    Miskolc, H-3501, Hungary
  • Szegedi Tudomanyegyetem, I.sz. Belgyogyaszati Klinika
    Szeged, H-6701, Hungary
  • Bnai Zion Medical Center
    Haifa, 31048, Israel
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Strauss Medical Center
    Jerusalem, 95146, Israel
  • Meir Hospital
    Kfar Saba, 44281, Israel
  • Rabin Medical Center, Bellinson Hospital
    Petah Tikva, 48100, Israel
  • Sheba Medical Center
    Ramat Gan, 52621, Israel
  • Kaplan Medical Center
    Rehovot, 76100, Israel
  • Erasmus MC, Department of Gastroenterology and Hepatology
    Rotterdam, 3015 CE, Netherlands
  • Samodzielny Publiczny Centralny Szpital Kliniczny Slaskiej AM
    Katowice, 40-752, Poland
  • Zakaznych Szpitala Uniwersyteckiego w Krakowie
    Krakow, 31-531, Poland
  • Korektalnej Uniwersytetu Medycznego w Lodzi
    Lodz, 90-647, Poland
  • University Hospital Olomouc, 2nd Internal Department
    Olomouc, 775 20, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 2 im. Heliodora
    Poznan, 06-355, Poland
  • Samodzielny Publiczny Centralny Szpital
    Warszawa, 02-097, Poland
  • Katedra Klinika Gastroenterologi, Akedemil Medycanej we Wroclawiu
    Wroclaw, 50-326, Poland
  • Bristol Royal Infirmary, Dept. of Gastroenterology
    Bristol, BS2 8HW, United Kingdom
  • Countess of Chester Hospital
    Chester, CH2 1UL, United Kingdom
  • Crosshouse Hospital
    Kilmarnock, KA2 0BE, United Kingdom
  • Leicester General Hospital - GI Research Unit
    Leicester, LE5 4PW, United Kingdom
  • University College London Hospital, Dept. of Gastroenterology
    London, NW1 2BU, United Kingdom
  • John Radcliffe Hospital, Dept. of Gastroenterology
    Oxford, OX3 9DU, United Kingdom
08

References and documents

Publications

  • Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992 Jun;14(4):309-17. doi: 10.1097/00004836-199206000-00009. PubMed 1607607 ↗
  • Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001 May 31;411(6837):599-603. doi: 10.1038/35079107. PubMed 11385576 ↗
  • Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001 May 31;411(6837):603-6. doi: 10.1038/35079114. PubMed 11385577 ↗
  • Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979 Oct;77(4 Pt 2):843-6. PubMed 467941 ↗
  • Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr;122(4):875-80. doi: 10.1053/gast.2002.32362. PubMed 11910338 ↗
  • Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980 Jun;21(6):525-7. doi: 10.1136/gut.21.6.525. PubMed 7429313 ↗
  • Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology. 1975 Apr;68(4 Pt 1):627-35. No abstract available. PubMed 1123132 ↗
  • Gray BK, Lockhartmummery HE, Morson BC. Crohn's disease of the anal region. Gut. 1965 Dec;6(6):515-24. doi: 10.1136/gut.6.6.515. No abstract available. PubMed 5857889 ↗
  • Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med. 2001 Nov 20;135(10):906-18. doi: 10.7326/0003-4819-135-10-200111200-00011. PubMed 11712881 ↗
  • Schwartz DA, Herdman CR. Review article: The medical treatment of Crohn's perianal fistulas. Aliment Pharmacol Ther. 2004 May 1;19(9):953-67. doi: 10.1111/j.1365-2036.2004.01917.x. PubMed 15113362 ↗
  • Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398-405. doi: 10.1056/NEJM199905063401804. PubMed 10228190 ↗
  • Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980 May 1;302(18):981-7. doi: 10.1056/NEJM198005013021801. PubMed 6102739 ↗
  • Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 4;359(9317):1541-9. doi: 10.1016/S0140-6736(02)08512-4. PubMed 12047962 ↗
  • Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 Feb 26;350(9):876-85. doi: 10.1056/NEJMoa030815. PubMed 14985485 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Mar 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2006
First posted
May 3, 2006
Start
Mar 2006
Primary completionActual
Mar 2008
CompletionActual
Sep 2008
Results delay requested
May 27, 2014
Last update
May 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00321412
Lead sponsor
Ocera Therapeutics
Responsible party
Sponsor
First posted
May 3, 2006
Start date
Mar 2006
Primary completion
Mar 2008
Completion
Sep 2008
Last update
May 30, 2014

Study contacts

Laurent Fischer, MD
study director · Ocera Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AST 120 · Charcoal

Start the discussion